Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of changes in trough levels (TLs) and anti-drug antibodies (ADAs) formation and disease activity after switching from originator infliximab to biosimilar infliximab in inflammatory bowel disease patients

Next Previous
Trial Profile

Evaluation of changes in trough levels (TLs) and anti-drug antibodies (ADAs) formation and disease activity after switching from originator infliximab to biosimilar infliximab in inflammatory bowel disease patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

    • Most Recent Events

    • 18 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top